Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOCYTE AMI-3 of intravenous FDY-5301 in anterior STEMI
NL-OMON54138Phase 3Recruiting
- Sponsor
- Faraday Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) and acute ST-segment elevation myocardial infarction (STEMI) comparing FDY-5301 with Placebo (2 arms). Primary endpoint: Primary composite endpoint. Started Aug 2022; status: recruiting.
02
Drugs
Sodium iodide
03
Conditions
myocardial infarction (MI)acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NL-OMON54138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54138.